AR071719A1 - Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion - Google Patents

Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion

Info

Publication number
AR071719A1
AR071719A1 ARP090101711A ARP090101711A AR071719A1 AR 071719 A1 AR071719 A1 AR 071719A1 AR P090101711 A ARP090101711 A AR P090101711A AR P090101711 A ARP090101711 A AR P090101711A AR 071719 A1 AR071719 A1 AR 071719A1
Authority
AR
Argentina
Prior art keywords
alkyl
3alkyl
piperazin
alkyloxy
oxo
Prior art date
Application number
ARP090101711A
Other languages
English (en)
Inventor
Bradford S Hamilton
Matthias Eckhardt
Frank Himmelsbach
Joerg Kley
Thorsten Lehmann-Lintz
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR071719A1 publication Critical patent/AR071719A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Abstract

Particularmente, los compuestos son inhibidores de la 11b-hidroxiesteroide deshidrogenasa (HSD) 1 y, por lo tanto, son adecuados para el tratamiento y la prevencion de enfermedades que pueden estar influenciadas por la inhibicion de esta enzima, tales como enfermedades metabolicas, en particular diabetes de tipo 2, obesidad y dislipidemia. Reivindicacion 1: Compuestos caracterizados porque tienen formula (1) en la que X representa CH o N; m, n, o, independientemente entre s¡, representan 0, 1 o 2, donde la estructura nucleo de azacicloalqueno bic¡clico de formula general (1) anillada con el anillo A y unida al grupo carbonilo est  opcionalmente sustituida con 1, 2, o m s sustituyentes, preferiblemente con 1 a 5, seleccionados independientemente entre s¡ entre el grupo que consiste en R11 y R12; A representa un anillo benzo, que est  opcionalmente sustituido con uno a cuatro sustituyentes seleccionados independientemente entre s¡ entre R1 o donde 2  tomos de C adyacentes est n opcionalmente sustituidos con R2 y R3 y uno o dos  tomos de carbono est n opcionalmente sustituidos independientemente con sustituyentes seleccionados entre R1; o un anillo pirido, que est  opcionalmente sustituido con uno a tres sustituyentes, preferiblemente 1, 2, 3 o 4 sustituyentes, seleccionados independientemente entre s¡ entre R1 o donde 2  tomos de C adyacentes est n opcionalmente sustituidos con R2 y R3 y un  tomo de carbono est  opcionalmente sustituido con R1; o un anillo pirrolo, furo, tieno, piridazino o pirazino donde cada uno de dichos anillos est  opcionalmente sustituido con uno o dos sustituyentes, seleccionados independientemente entre s¡ entre R1 o donde 2  tomos de C adyacentes de cada uno de dichos anillos est n opcionalmente sustituidos con R2 y R3; o un anillo pirimido, que est  opcionalmente sustituido con uno o dos sustituyentes, seleccionados independientemente entre s¡ entre R1, o un anillo pirazolo, imidazo, oxazolo, tiazolo, isoxazolo o isotiazolo donde cada uno de dichos anillos est  opcionalmente sustituido con R1; o un anillo 1,2,3-triazolo sustituido con RN; y B representa un grupo cicloalquilo monoc¡clico de 5 a 8 miembros, espiroc¡clico de 8 a 12 miembros, bic¡clico de 6 a 12 miembros o tric¡clico de 9 a 15 miembros, estando cada uno de ellos opcionalmente saturado o parcialmente insaturado, y donde 1 o 2 grupos -CH2- se reemplazan opcionalmente por -NRN-, y donde 1 a 4 grupos -CH2-, que no est n unidos directamente uno a otro, se reemplazan opcionalmente independientemente entre s¡ por O, S, carbonilo o sulfonilo, y donde 1 o 2 grupos -CH se reemplazan opcionalmente por N, y donde cada grupo cicloalquilo mencionado anteriormente est  opcionalmente sustituido con uno o m s sustituyentes seleccionados independientemente entre s¡ entre L1, y donde cada uno de dichos grupos cicloalquilo est  opcionalmente sustituido con 1 o 2 sustituyentes seleccionados independientemente entre s¡ entre L2, y donde 2  tomos de C adyacentes de cada uno de dichos grupos cicloalquilo est n opcionalmente sustituidos con L3 y L4, y donde 2  tomos de C adyacentes de cada uno de dichos grupos cicloalquilo est n opcionalmente sustituidos con L5 y L6, con la condicion de que dos de L3 a L6 no puedan unirse al mismo  tomo de carbono; RN independientemente entre s¡, representa hidrogeno, alquilo C1-6, alquenilo C3-6, alquinilo C3-6, cicloalquilo C3-6, (het)arilo, alquilcarbonilo C1-4, alquiloxicarbonilo C1-4, alquilaminocarbonilo C1-4, di-(alquil C1-3)aminocarbonilo, alquilsulfonilo C1-4, (het)arilcarbonilo, (het)arilaminocarbonilo o (het)arilsulfonilo, donde cada grupo alquilo, alquenilo y alquinilo est  opcionalmente mono o polisustituido con fluor, y est  opcionalmente monosustituido con hidroxi, alcoxi C1-4, alquilsulfanilo C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, amino, alquilamino C1-4, di-(alquil C1-4)amino, alquilcarbonilamino C1-4, ciano, carboxi, alcoxicarbonilo C1-4, aminocarbonilo, alquilaminocarbonilo C1-4, di-(alquil C1-4)aminocarbonilo o (het)arilo; R1 representa fluor, cloro, bromo, yodo, ciano, nitro, alquilo C1-4, hidroxi, alquiloxi C1-4, alqueniloxi C3-6, difluorometilo, trifluorometilo, difluorometoxi, trifluorometoxi, 2,2,2-trifluoro-1-hidroxietilo, 2,2,2-trifluoro-1-hidroxi-1-metiletilo, 2,2,2-trifluoro-1-hidroxi-1-(trifluorometil)etilo, cicloalquilo C3-6, cicloalquiloxi C3-6, cicloalquil C3-6-alquilo C1-3, cicloalquil C3-6-alquiloxi C1-3, tetrahidrofurano-3-iloxi, tetrahidropiran-3-iloxi, tetrahidropiran-4-iloxi, tetrahidrofuranoil-alquiloxi C1-3, tetrahidropiranil C1-3, (het)arilo, (het)ariloxi, (het)aril-alquilo C1-3, (het)aril-alquiloxi C1-3, (het)ariloxi-alquilo C1-3, alquil C1-3-carbonilo, (het)aril-carbonilo, amino, alquilamino C1-3, di-(alquil C1-3)amino, pirrolidin-1-ilo, 2-oxo-pirrolidin-1-ilo, piperidin-1-ilo, 2-oxo-piperidin-1-ilo, morfolin-4-ilo, 3-oxo-morfolin-4-ilo, piperazin-1-ilo, 2-oxo-piperazin-1-ilo, 3-oxo-piperazin-1-ilo, 4-(alquil C1-3)-piperazin-1-ilo, 4-(alquilcarbonil C1-4)-piperazin-1-ilo, 4-(cicloalquilcarbonil C3-6)-piperazin-1-ilo, 4-(alquiloxicarbonil C1-4)-piperazin-1-ilo, 4-(alquilsulfonil C1-4)-piperazin-1-ilo, 2-oxo-4-(alquil C1-3)-piperazin-1-ilo, 3-oxo-4-(alquil C1-3)-piperazin-1-ilo, alquil C1-3-carbonilamino, (het)aril-carbonilamino, (het)aril-alquil C1-3-carbonilamino, alquiloxi C1-3-carbonilamino, aminocarbonilamino, alquil C1-3-aminocarbonilamino, di-(alquil C1-3)aminocarbonilamino, pirrolidin-1-il-carbonilamino, piperidin-1-il-carbonilamino, morfolin-4-il-carbonilamino, piperazin-1-il-carbonilamino, 4-(alquil C1-3)-piperazin-1-il-carbonilamino, alquil C1-3-sulfonilamino, aminosulfonilamino, alquil C1-3amino-sulfonilamino, di-(alquil C1-3)amino-sulfonilamino, pirrolidin-1-il-sulfonilamino, piperidin-1-il-sulfonilamino, morfolin-4-il-sulfonilamino, piperazin-1-il-sulfonilamino, 4-(alquil C1-3)-piperazin-1-il-sulfonilamino, (alquiloxi C1-3-carbonilamino)carbonilamino, (het)arilsulfonilamino, (het)aril-alquil C1-3-sulfonilamino, N-(alquil C1-3)-alquil C1-3-carbonilamino, N-(alquil C1-3)-(het)arilcarbonilamino, N(alquil C1-3)-(het)aril-alquil C1-3-carbonilamino, N-(alquil C1-3)-alquiloxi C1-3-carbonilamino, N-(aminocarbonil)-alquilamino C1-3, N-(alquil C1-3-aminocarbonil)-alquilamino C1-3, N-[di-(alquil C1-3)aminocarbonil]-alquilamino C1-3, N-(alquil C1-3)-alquil C1-3-sulfonilamino, N-(alquil C1-3)-(het)arilsulfonilamino, N(alquil C1-3)-(het)aril-alquil C1-3-sulfonilamino, oxo-imidazolidin-1-ilo, 2,4-dioxo-imidazolidin-1-ilo, 2,5-dioxo-imidazolidin-1-ilo, 2-oxo-hexahidropirimidin-1-ilo, donde el  tomo de nitrogeno de la posicion 3 de los grupos mencionados anteriormente est  opcionalmente sustituido con metilo o etilo, (hidroxiimino)aminometilo, (alquiloxiimino C1-3)aminometilo, carboxi, alquiloxi C1-3-carbonilo, aminocarbonilo, alquil C1-3-aminocarbonilo, di-(alquil C1-3)-aminocarbonilo, pirrolidin-1-il-carbonilo, piperidin-1-il-carbonilo, morfolin-4-il-carbonilo, piperazin-1-il-carbonilo, 4-(alquil C1-3)-piperazin-1-il-carbonilo, carboxi-alquilo C1-3, alquiloxi C1-3-carbonil-alquilo C1-3, ciano-alquilo C1-3, aminocarbonil-alquilo C1-3, alquil C1-3-aminocarbonil-alquilo C1-3, di-(alquil C1-3)-aminocarbonil-alquilo C1-3, pirrolidin-1-il-carbonil-alquilo C1-3, piperidin-1-il-carbonil-alquilo C1-3, morfolin-4-iI-carbonil-alquilo C1-3, piperazin-1-il-carbonilalquilo C1-3, 4-(alquil C1-3)-piperazin-1-il-carbonil-alquilo C1-3, carboxi-alquiloxi C1-3, alquiloxi C1-3-carbonil-alquiloxi C1-3, ciano-alquiloxi C1-3, aminocarbonil-alquiloxi C1-3, alquil C1-3-aminocarbonil-alquiloxi C1-3, di-(alquil C1-3)-aminocarbonil-alquiloxi C1-3, pirrolidin-1-il-carbonil-alquiloxi C1-3, piperidin-1-il-carbonil-alquiloxi C1-3, morfolin-4-iI-carbonil-alquiloxi C1-3, piperazin-1-il-carbonilalquiloxi C1-3, 4-(alquil C1-3)-piperazin-1-il-carbonil-alquiloxi C1-3, hidroxi-alquilo C1-3, alquiloxi C1-3-alquilo C1-3, amino-alquilo C1-3, alquilamino C1-3-alquilo C1-3, di-(alquil C1-3)-amino-alquilo C1-3, pirrolidin-1-il-alquilo C1-3, alquil C1-4carbonil-amino-alquilo C1-3, N-(alquil C1-3)-alquil C1-4carbonil-amino-alquilo C1-3, 2-oxo-pirrolidin-1-iI-alquilo C1-3, piperidin-1-il-alquilo C1-3, 2-oxo-piperidin-1-il-alquilo C1-3, morfolin-4-il-alquilo C1-3, 3-oxo-morfolin-4-il-alquilo C1-3, piperazin-1-il-alquilo C1-3, 2-oxo-piperazin-1-il-alquilo C1-3, 3-oxo-piperazin-1-il-alquilo C1-3, 4-(alquil C1-3)-piperazin-1-il-alquilo C1-3, 2-oxo-4-(alquil C1-3)-piperazin-1-iI-alquilo C1-3, 3-oxo-4-(alquil C1-3)-piperazin-1-il-alquilo C1-3, hidroxi-alquiloxi C1-3, alquiloxi C1-3-alquiloxi C1-3, alquilsulfanil C1-3-alquiloxi C1-3, alquilsulfinil C1-3-alquiloxi C1-3, alquilsulfonil C1-3-alquiloxi C1-3, amino-alquiloxi C1-3 , alquilamino C1-3-alquiloxi C1-3, di-(alquil C1-3)-amino-alquiloxi C1-3, pirrolidin-1-il-alquiloxi C1-3, 2-oxo-pirrolidin-1-il-alquiloxi C1-3, piperidin-1-il-alquiloxi C1-3, 2-oxo-piperidin-1-il-alquiloxi C1-3, morfolin-4-il-alquiloxi C1-3, 3-oxo-morfolin-4-il-alquiloxi C1-3, piperazin-1-il-alquiloxi C1-3, 2-oxo-piperazin-1-il-alquiloxi C1-3, 3-oxo-piperazin-1-il-alquiloxi C1-3, 4-(alquil C1-3)-piperazin-1-il-alquiloxi C1-3, 2-oxo-4-(alquil C1-3)-piperazin-1-il-alquiloxi C1-3, 3-oxo-4-(alquil C1-3)-piperazin-1-il-alquiloxi C1-3, alquilsulfanilo C1-3, alquilsulfinilo C1-3, alquilsulfonilo C1-3, alquilsulfoniloxi C1-3, (het)arilsulfonilo, (het)arilsulfoniloxi, trifluorometilsulfanilo, trifluorometilsulfinilo, trifluorometilsulfonilo, aminosulfonilo, alquil C1-3-aminosulfonilo, di-(alquil C1-3)-aminosulfonilo, pirrolidin-1-il-sulfonilo, piperidin-1-il-sulfonilo, morfolin-4-il-sulfonilo, piperazin-1-il-sulfonilo o 4-(alquil C1-3)-piperazin-1-il-sulfonilo-, donde los heterociclos saturados y los anillos cicloalquilo mencionados anteriormente est n opcionalmente sustituidos con uno o dos grupos seleccionados independientemente entre fluor, alquilo C1-3, alcoxi C1-3, alcoxi C1-3-alquilo C1-3 e hidroxi; R2, R3 est n unidos entre s¡ para formar un grupo puente metilendioxi, etilendioxi o alquileno C3-5,
ARP090101711A 2008-05-13 2009-05-12 Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion AR071719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08156122 2008-05-13

Publications (1)

Publication Number Publication Date
AR071719A1 true AR071719A1 (es) 2010-07-07

Family

ID=41319098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101711A AR071719A1 (es) 2008-05-13 2009-05-12 Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion

Country Status (8)

Country Link
US (2) US8765780B2 (es)
EP (1) EP2288596B1 (es)
JP (1) JP5711115B2 (es)
AR (1) AR071719A1 (es)
CA (1) CA2724214A1 (es)
CL (1) CL2009001151A1 (es)
TW (1) TW200950780A (es)
WO (1) WO2009138386A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009063061A2 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
EP2245014B1 (en) * 2008-02-12 2011-11-02 Boehringer Ingelheim International GmbH Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
WO2009102460A2 (en) 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
CA2723039A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5301563B2 (ja) 2008-05-01 2013-09-25 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
CA2724214A1 (en) 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
CA2738453C (en) 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
CA2744946A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MY192815A (en) * 2011-12-22 2022-09-09 Connexios Life Sciences Pvt Ltd Derivatives of aza adamantanes and uses thereof
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
EP3022207A4 (en) * 2013-07-15 2016-12-07 Univ Texas COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER, NEUROLOGICAL ILLNESS, ETHANOL DENTURE, SCARENESS, DEPRESSION AND NEUROPATHIC PAIN
US9656962B2 (en) 2013-12-26 2017-05-23 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
AU2017257153A1 (en) 2016-04-29 2018-11-22 Board Of Regents, The University Of Texas System Sigma receptor binders
WO2021210014A1 (en) * 2020-04-14 2021-10-21 Shiv Nadar University Therapeutic novel chemical entities and method thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378587A (en) 1963-03-14 1968-04-16 Du Pont 3, 3'-diaminomethyl-1, 1'-biadamantane
NL127995C (es) 1963-12-20 Geigy Ag J R
US3341538A (en) 1965-06-18 1967-09-12 Geigy Chem Corp Certain 2, 6-methano-3-benzazocines
US3474106A (en) 1966-11-16 1969-10-21 Hoffmann La Roche 3-lower-alkyl - 1,2,3,4,5,6 - hexahydro-6,11-di-lower-alkyl - 9-diethylaminomethyl-2,6-methano-3-benzazocin-8-ols
US3539637A (en) * 1967-04-10 1970-11-10 Geigy Chem Corp N-carbamyl and thiocarbamyl-2,3,4,5-tetrahydro - 1,4 - methano - 1h - 3-benzazepines
DE2108954A1 (en) 1971-02-25 1972-09-07 Boehringer Sohn Ingelheim 2-(furylmethyl)-6,7-benzomorphans - useful as cns active agents
GB1304175A (es) 1969-03-31 1973-01-24
DE2105743C3 (de) 1971-02-08 1979-11-29 Boehringer Sohn Ingelheim 2-(Furylmethyl)- a -5,9-dialkyl -6,7benzomorphane, Verfahren zu ihrer Herstellung und deren Verwendung
CS166803B2 (es) 1971-02-08 1976-03-29 Boehringer Sohn Ingelheim
US4043927A (en) 1972-03-07 1977-08-23 Sun Ventures, Inc. Friction or tractive drive containing ethers of adamantanes
US3856795A (en) 1972-04-25 1974-12-24 American Home Prod Process for preparation of secondary amines from tertiary amines
DE2229695A1 (de) 1972-06-19 1974-01-31 Boehringer Sohn Ingelheim 2-(heteroaryl-methyl)-5,9 beta-dialkyl6,7-benzomorphane, deren saeureadditionssalze sowie verfahren zu deren herstellung
DE2338369A1 (de) 1973-07-26 1975-02-13 Schering Ag Mikrobiologische hydroxylierung von 2,6-methano-3-benzazocinen
SU510999A3 (ru) 1973-10-27 1976-04-15 К.Х.Берингер Зон, (Фирма) Способ получени (метоксиметил-фурилметил)6,7-бензоморфанов илиморфинанов
US4009171A (en) 1974-02-21 1977-02-22 Sterling Drug Inc. N-acylated-11-oxygenated-2,6-methano-3-benzazocine intermediates
DE2411382C3 (de) 1974-03-09 1979-09-06 C.H. Boehringer Sohn, 6507 Ingelheim 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung
DE2437610A1 (de) 1974-08-05 1976-02-26 Boehringer Sohn Ingelheim Neue 5,9-beta-disubstituierte 2-tetrahydrofurfuryl-6,7-benzomorphane, deren saeureadditionssalze, ihre verwendung als arzneimittel und verfahren zu deren herstellung
GB1513961A (en) 1975-02-25 1978-06-14 Acf Chemiefarma Nv 6,7-benzomorphans method for their preparation and intermediates
US4108857A (en) 1975-08-18 1978-08-22 Sterling Drug Inc. Imidazolylmethyl methanobenzazocines
JPS5919542B2 (ja) 1976-06-24 1984-05-07 旭電化工業株式会社 ベンズアゾシン誘導体
DE2828039A1 (de) 1978-06-26 1980-01-10 Boehringer Sohn Ingelheim 2-(2-alkoxyethyl)-2'-hydroxy-6,7-benzomorphane deren saeureadditionssalze diese enthaltende arzneimittel und verfahren zu deren herstellung
US5607941A (en) 1992-06-26 1997-03-04 Boehringer Ingelheim Kg Useful for treating neurodegenerative diseases
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
GB9510459D0 (en) 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
GB9517622D0 (en) 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
GB9623944D0 (en) 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
EA003925B1 (ru) 1997-05-22 2003-10-30 Дж.Д.Сирл Энд Ко ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p 38 КИНАЗЫ
US6145103A (en) 1998-04-07 2000-11-07 Advanced Micro Devices, Inc. Emulator support mode for disabling and reconfiguring timeouts of a watchdog timer
FR2796940B1 (fr) 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
WO2001055063A1 (fr) 2000-01-25 2001-08-02 Idemitsu Petrochemical Co., Ltd. Nouveaux composes a base de bisadamantane, procedes de production et nouveaux derives de bisadamantane
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
JP2003057815A (ja) 2001-06-05 2003-02-28 Sumitomo Chem Co Ltd 化学増幅型レジスト組成物
WO2003097608A2 (en) 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP1610789B1 (en) 2003-03-26 2010-07-21 Merck Sharp & Dohme Corp. Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
JP2007015930A (ja) * 2004-09-13 2007-01-25 Ono Pharmaceut Co Ltd 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
DE602005007344D1 (de) 2004-05-07 2008-07-17 Janssen Pharmaceutica Nv Adamantyl pyrrolidin-2-on-derivate als 11-beta hydroxysteroid dehydrogenas inhibitoren
JP5014983B2 (ja) 2004-05-07 2012-08-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのピロリジン−２−オン及びピペリジン−２−オン誘導体
EP1786774B1 (en) 2004-08-30 2009-10-14 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
CA2581745A1 (en) 2004-10-13 2006-04-27 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
JPWO2006104280A1 (ja) 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
JP4935196B2 (ja) 2005-06-08 2012-05-23 住友ベークライト株式会社 ベンゾオキサゾール前駆体、樹脂組成物およびそれを用いたコーティングワニス、樹脂膜並びに半導体装置
JP4815883B2 (ja) 2005-06-08 2011-11-16 住友ベークライト株式会社 ビアダマンタン誘導体
JP2009514818A (ja) 2005-11-01 2009-04-09 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの製薬学的用途
JP2007140188A (ja) 2005-11-18 2007-06-07 Fujifilm Corp ポジ型感光性組成物及びそれを用いたパターン形成方法
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US8865707B2 (en) 2005-12-30 2014-10-21 Merck Sharp & Dohme Corp. Cholesteryl ester transfer protein inhibitors
JP2007254409A (ja) 2006-03-24 2007-10-04 Taisho Pharmaceut Co Ltd イミダゾリジノン誘導体
JP2007269721A (ja) 2006-03-31 2007-10-18 Daicel Chem Ind Ltd ビアダマンタンカルボン酸誘導体の製造法
US8088776B2 (en) 2006-04-21 2012-01-03 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PT2029529E (pt) 2006-04-24 2010-09-02 Lilly Co Eli Pirrolidinonas substituídas como inibidores de 11 betahidroxiesteróide desidrogenase
BRPI0710231A2 (pt) 2006-04-25 2011-08-02 Lilly Co Eli composto, composição farmacêutica, e, intermediário para a preparação de um composto
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
TW200829171A (en) 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009063061A2 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
WO2009102428A2 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
EP2245014B1 (en) 2008-02-12 2011-11-02 Boehringer Ingelheim International GmbH Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
WO2009102460A2 (en) 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US20110105504A1 (en) 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5301563B2 (ja) 2008-05-01 2013-09-25 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
CA2724214A1 (en) 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8309597B2 (en) 2008-07-25 2012-11-13 Boehringer Ingelheim International Gmbh 1,1′-diadamantyl carboxylic acids, medicaments containing such compounds and their use
WO2010023161A1 (en) 2008-08-25 2010-03-04 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
CA2738453C (en) 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
TWI531571B (zh) 2009-11-06 2016-05-01 維它藥物公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜芳基羰基衍生物
TWI537258B (zh) 2010-11-05 2016-06-11 百靈佳殷格翰國際股份有限公司 六氫茚并吡啶及八氫苯并喹啉之芳基－及雜環芳基羰基衍生物
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives

Also Published As

Publication number Publication date
US20110269791A1 (en) 2011-11-03
EP2288596A2 (en) 2011-03-02
JP2011520832A (ja) 2011-07-21
EP2288596B1 (en) 2016-11-30
JP5711115B2 (ja) 2015-04-30
US9073870B2 (en) 2015-07-07
CL2009001151A1 (es) 2010-08-13
US20140179669A1 (en) 2014-06-26
TW200950780A (en) 2009-12-16
CA2724214A1 (en) 2009-11-19
US8765780B2 (en) 2014-07-01
WO2009138386A3 (en) 2010-02-11
WO2009138386A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AR071719A1 (es) Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion
AR070526A1 (es) Derivados de urea de benzomorfanos y estructuras relacionadas, una composicion farmaceutica que incluye al compuesto y un procedimiento de preparacion del mismo
AR069545A1 (es) Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
CN107735087B (zh) 组蛋白脱乙酰酶抑制剂及其组合物和使用方法
ES2915266T3 (es) Derivados de N-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarínico 4 (M4) para el tratamiento de enfermedades neurológicas
JP6647592B2 (ja) ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
AU2022203948A1 (en) Apoptosis-Inducing Agents
US20110237578A1 (en) Amide compounds, compositions and uses thereof
Basiri et al. An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study
AR066502A1 (es) Compuestos amino- heterociclicos
WO2006018735A3 (en) Triazolopyridine compounds
AR065354A1 (es) Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4.
MXPA06014572A (es) Compuestos amido y su uso como farmaceuticos.
NZ612041A (en) Compounds and their use as bace inhibitors
AR057034A1 (es) Metodos para purificar tigeciclina
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
WO2006018727A3 (en) Triazolopyridine compounds useful for the treatment of inflammation
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR073920A1 (es) Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
MX336224B (es) Quinolinas sustituidas y su uso como medicamentos.
HRP20050708A2 (en) Piperidine-benzenesulfonamide derivatives
NZ594230A (en) Inhibitors of beta-secretase
PE20030440A1 (es) Fenilsulfonamidas como antagonistas de ccr3
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure